Lim Jonathan E 4
4 · Boundless Bio, Inc. · Filed Apr 4, 2024
Insider Transaction Report
Form 4
Lim Jonathan E
Director
Transactions
- Conversion
Common Stock
2024-04-02+525,274→ 550,915 total(indirect: By LLC) - Conversion
Series A Convertible Preferred Stock
2024-04-02−512,820→ 0 total(indirect: By LLC)→ Common Stock (512,820 underlying) - Conversion
Series B Convertible Preferred Stock
2024-04-02−5,128→ 0 total(indirect: By LLC)→ Common Stock (5,128 underlying) - Conversion
Series C Convertible Preferred Stock
2024-04-02−7,326→ 0 total(indirect: By LLC)→ Common Stock (7,326 underlying)
Holdings
- 102,564
Common Stock
Footnotes (2)
- [F1]Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
- [F2]Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.